Immunome opened lower at $18.86, compared with its previous close of $19.07. In the last trading session, the stock traded between $18.02 and $19.06. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Immunome is now worth
$ 102.44
Giving a profit of
$ 2.44 (2.44%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 10 Analysts
Buy
90%
Hold
10%
Sell
0%
Markets Today
Today's Change
$-0.37 (-1.91%)
Day High
$19.06
Day Low
$18.02
Day Open
$18.86
Prev Close
$19.07
Volume
10,82,096
1W Return
-4.24%
1M Return
-2.34%
3M Return
-28.70%
6M Return
-18.67%
1Y Return
6.76%
Fundamentals
Market Cap ($ Mn)
2,209
PE Ratio
-
PB Ratio
5.95
PEG Ratio
-
ROE
-64.14%
ROCE
-66.80%
EPS (TTM)
$-0.75
Investment Returns
1 Week
-4.24%
1 Month
-2.34%
3 Months
-28.70%
6 Months
-18.67%
9 Months
-20.10%
Financials
Quarterly
All values in $ Mn
2.9
Mar 25
4.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
10Nov
Immunome Q3 Results: Loss widens to 76 cents; analysts cut targets
Immunome posted a Q3 loss of 76 cents per share, missing estimates of 63 cents. Stifel lowered its price target to $23 while maintaining a Hold rating. Piper Sandler cut its price target to $30 but kept an Overweight rating. Shares fell 4.6% to $18.48 following the earnings release.
2 days ago
10Nov
Immunome files prospectus for offering of 4.425 million common shares
Immunome Inc filed a prospectus for an equity offering. The offering comprises 4.425 million common shares. The document was submitted to the US Securities and Exchange Commission.
3 days ago
7Nov
Immunome grants inducement stock options and RSUs to new hires
Immunome granted 206,700 stock options and 103,350 RSUs to new employees. Option exercise price set at $19.59 based on November 2, 2026 closing price. Awards vest over four years under Nasdaq Listing Rule 5635(c)(4).
6 days ago
16Oct
William Blair initiates coverage on Immunome with Outperform rating
William Blair initiated coverage on Immunome Inc. Analyst Alethia Young assigned an Outperform rating. Price target set at $40 per share.
27 days ago
2Sep
Immunome management to present at Wainwright conference on Sept 14
Immunome management presents at H.C. Wainwright conference on Sept 14, 2026. Live webcast available on company website with 30-day replay access. Pipeline includes varegacestat with FDA-accepted NDA and multiple ADCs.
2mo ago
13Aug
Truist raises Immunome price target to $38, maintains Buy rating
Truist Securities maintains a Buy rating on Immunome (NASDAQ: IMNM). Analyst Supawat Thongthip raised the price target from $37 to $38, signaling confidence in the stock's potential.
